What this comparison tells you
GLP-1 receptor agonist
Liraglutide
EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use in the reviewed sources. It does not mean the product is safe or effective for everyone.- Evidence type
- Health results for approved uses
- Approval
- FDA-approved products exist for specific indications
- Approved products
- Victoza · Saxenda
- Sports status
- Not assessed
- Sources used
- 4 sources
- Last reviewed
- July 23, 2026
An established prescription medicine. Its evidence applies to specific products, uses, groups of people, and current labels.
GLP-1 receptor agonist
Semaglutide
EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use in the reviewed sources. It does not mean the product is safe or effective for everyone.- Evidence type
- Health results for approved uses
- Approval
- Yes. Some semaglutide prescription products are FDA-approved for specific uses
- Approved products
- Ozempic · Wegovy · Wegovy HD · Rybelsus
- Sports status
- No prohibition identified
- Sources used
- 8 sources
- Last reviewed
- August 30, 2026
This review covers Ozempic, Rybelsus, Wegovy, and the Wegovy HD strength. Their forms, approved uses, and labels differ.
How the evidence compares
These are separate questions, not one score. A peptide can be well understood in one area and uncertain in another.
Both peptide columns stay aligned. Read across each row to compare the same question. On smaller screens, each question shows both records together.
Each question shows both records together.
| Question checked | LiraglutideEstablished | SemaglutideEstablished |
|---|---|---|
| Health benefitsDid people's health improve? | LiraglutideStrong Large randomized programs support defined glycemic, cardiovascular, and weight-management outcomes. | SemaglutideStrong Large studies support the approved uses listed on each product label. |
| Body changes in peopleWhat body changes did studies in people measure? | LiraglutideStrong Approved labels characterize product-specific exposure, pharmacodynamics, and interactions. | SemaglutideStrong Studies have measured how approved products act in the body and how the body processes them. |
| Known risksWhat do we know about risks in people? | LiraglutideStrong Current labels describe contraindications, warnings, adverse reactions, and monitoring. | SemaglutideStrong Current product labels list known risks, warnings, and when each product should not be used. |
| Exact productDo we know what the product contains and how well it was made? | LiraglutideStrong High for authentic approved products; evidence does not transfer automatically to unapproved versions. | SemaglutideStrong High for an authentic approved product. This evidence does not transfer to every compounded version. |
| Approval statusIs there a reviewed product for a specific use? | Liraglutide FDA-approved products exist for specific indications | Semaglutide Yes. Some semaglutide prescription products are FDA-approved for specific uses |
Questions to ask before you compare
Use these questions to see whether the records match.
- 01
Which exact product is being compared, not just which ingredient?
- 02
Which use and which people does each product label cover?
- 03
Does a study result apply to the same product, people, and time period?
- 04
What does this comparison not tell you about safety or personal use?
What sources were used
The number of sources does not prove strength. Different sources answer different questions. A drug label, a trial, a cell study, and an agency review do not mean the same thing.
Liraglutide
4 sources used
- Drug label2
- Randomized trial1
- Regulatory1
Studies and FDA-reviewed labels support specific outcomes. LEADER studied heart and blood-vessel outcomes in adults with type 2 diabetes at high cardiovascular risk. Saxenda has a separate chronic weight-management label.
These results do not show the same benefit for every person. They do not establish an anti-aging effect or show that approved products are equivalent to compounded, counterfeit, or research-labeled material.
Semaglutide
8 sources used
- Drug label3
- Regulatory2
- Anti-doping1
- Preclinical1
- Reference1
FDA-reviewed semaglutide products have approved uses and official labels. Each label says who the product is for, its warnings, side effects, and directions. Read the current label for the exact product. Do not rely on the ingredient name alone.
A shared ingredient name does not make two products the same. Evidence from an approved product does not automatically apply to an unapproved, compounded, counterfeit, or research-labeled product. The name alone does not prove equal quality, safety, or results.
Fact checks for each peptide
Each result applies only to the statement shown. Open its record to see the version and sources.
Liraglutide
“Liraglutide has established human outcome evidence.”
Yes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.
- Evidence used
- Health results from a study with randomly assigned groups
- What this result covers
- Approved liraglutide products used in the populations and indications studied.
“Every product sold as liraglutide is clinically equivalent.”
Approved-product evidence includes product quality and labeling that cannot be assumed for every compounded or unapproved item.
- Evidence used
- Official record or product label
- What this result covers
- Product identity, formulation, quality, and labeling all matter.
“Cardiovascular trial results prove a universal longevity benefit.”
LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.
- Evidence used
- Health results from a study with randomly assigned groups
- What this result covers
- Adults with type 2 diabetes and high cardiovascular risk in LEADER.
Semaglutide
“Semaglutide is FDA-approved.”
FDA approves a specific product for specific uses. The current Wegovy label lists different forms, groups of people, uses, and limits.
- Evidence used
- Official record or product label
- What this result covers
- The exact semaglutide products, forms, people, and uses named in current FDA labels.
“Compounded semaglutide is the same as an approved product.”
FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
- Evidence used
- Official record or product label
- What this result covers
- Compounded or otherwise unapproved semaglutide products compared with FDA-approved products.
“A result in one population proves the same benefit for everyone.”
A study supports only the people, product form, dose, length, approved use, and result that it tested.
- Evidence used
- Health results from a study with randomly assigned groups
- What this result covers
- The people, product forms, measured results, and study lengths described in the cited product record.
Products with the same ingredient can differ
Evidence applies to the exact product used in a study. Check the peptide's amino-acid order, ingredients and form, how it enters the body, and where it came from. A shared ingredient name does not prove that another vial has the same benefits or risks.
Liraglutide
31 amino acids · acylated GLP-1 analogue
The ingredient name alone does not tell you which approved product the evidence covers. Liraglutide is an active ingredient. Victoza and Saxenda are distinct approved products with different labeled indications and product-specific prescribing information.
Victoza
November 2024- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Type 2 diabetes uses and labeled populations defined in the current product prescribing information.
Saxenda
February 2026- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Chronic weight management in the adult and pediatric populations defined in the current label.
- Type 2 diabetes for labeled populations
- Chronic weight management for labeled populations
Semaglutide
31 amino acids · modified peptide
Ozempic, Rybelsus, and Wegovy are distinct approved products. Wegovy HD is a higher-dose Wegovy injection strength. Evidence for one product or form does not automatically apply to another.
Ozempic
May 2026- How it enters the body
- Injection under the skin
- Use and people covered
- Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes and established heart disease. It covers kidney-risk reduction in adults with type 2 diabetes and chronic kidney disease.
Rybelsus
October 2025- How it enters the body
- Tablet by mouth
- Use and people covered
- Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes who are at high risk. It is not approved for weight management.
Wegovy
June 2026- How it enters the body
- Injection under the skin or tablet by mouth
- Use and people covered
- The injection label covers weight management in defined adults and children age 12 and older. It also covers heart-risk reduction in defined adults. MASH is a liver disease. When used with a reduced-calorie diet and increased physical activity, the injection label covers MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). The tablet label covers adult weight management and heart-risk reduction.
Wegovy HD
June 2026- How it enters the body
- Injection under the skin
- Use and people covered
- The 7.2 mg Wegovy injection strength for the adult weight-management group named in the label.
- Ozempic: blood-sugar control for adults with type 2 diabetes
- Ozempic: heart-risk reduction for adults with type 2 diabetes and established heart disease
- Ozempic: kidney- and heart-risk reduction for adults with type 2 diabetes and chronic kidney disease
- Rybelsus: blood-sugar control for adults with type 2 diabetes
- Rybelsus: heart-risk reduction for adults with type 2 diabetes who are at high risk
- Wegovy injection: weight management for the adults and children age 12 and older named in the label
- Wegovy tablets: weight management for the adults named in the label
- Wegovy injection and tablets: heart-risk reduction for the adults named in the label
- Wegovy injection, with a reduced-calorie diet and increased physical activity: MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). FDA granted accelerated approval after improvements in MASH and liver scarring. Continued approval can depend on a later study that confirms benefit.
Sports rules and safety limits
These statuses do not give personal clearance to compete.
Liraglutide
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
ReviewedThe current label has important reasons a product may not be appropriate, plus warnings and precautions. This guide does not determine eligibility or provide dose, titration, or product-switching instructions.
Semaglutide
No ban was identified in the checked 2026 WADA record. WADA monitors markers of semaglutide in and out of competition. Monitoring is not the same as a ban. Check the current list and your sport's rules.
Reviewed Read the governing record ↗This guide does not recommend a product, say who can use it, or give dosing instructions. A licensed clinician must use the current label and a person's medical history to make treatment decisions.
Two ingredients that act on the same body signal
Liraglutide and semaglutide are both GLP-1 receptor agonists. GLP-1 is a body signal that helps control blood sugar and appetite. Both records list 31 amino acids. Each is a changed (modified) form of GLP-1.
Each one is an ingredient, not a product. The ingredient name alone does not tell you the product, its form, its approved use, or the people its label covers.
Both are graded Established, with approved human outcomes. That evidence belongs to specific approved products used as their labels describe.
Which brand names contain each ingredient
Liraglutide is the ingredient in two FDA-approved products, Victoza and Saxenda. Both are injections under the skin. Victoza's label covers type 2 diabetes uses for the people it names. Saxenda's label covers chronic weight management in the adults and children it names.
Semaglutide is the ingredient in Ozempic, Rybelsus, Wegovy, and Wegovy HD. Ozempic is an injection under the skin for adults with type 2 diabetes. Its label covers blood-sugar control. It also covers lowering heart risk in adults with type 2 diabetes and established heart disease.
The Ozempic label also covers lowering kidney risk in adults with type 2 diabetes and chronic kidney disease. Rybelsus is a tablet taken by mouth for adults with type 2 diabetes. Its label covers blood-sugar control and lowering heart risk in those at high risk. Rybelsus is not approved for weight management.
Wegovy comes as an injection under the skin and as a tablet. The injection label covers weight management in defined adults and children age 12 and older. The tablet label covers weight management in the adults it names. Both forms also cover lowering heart risk in defined adults.
The Wegovy injection label also covers MASH, a liver disease. It covers adults without cirrhosis who have moderate to advanced liver scarring (F2–F3), used with a reduced-calorie diet and more physical activity.
FDA gave the MASH use accelerated approval after improvements in MASH and liver scarring. Continued approval can depend on a later study that confirms benefit. Wegovy HD is the 7.2 mg Wegovy injection strength for the adult weight-management group named in the label.
Victoza vs Ozempic and Saxenda vs Wegovy
Victoza and Ozempic are the injectable type 2 diabetes products in these records. Victoza contains liraglutide. Ozempic contains semaglutide. Rybelsus is the semaglutide tablet for type 2 diabetes.
Saxenda and Wegovy are the weight-management products in these records. Saxenda contains liraglutide. Wegovy and Wegovy HD contain semaglutide. Each label names the groups of people it covers.
Products with the same ingredient are still separate products. Victoza and Saxenda have different labeled uses and their own prescribing information. The semaglutide record says evidence for one product or form does not automatically apply to another.
What studies in people show
The liraglutide record cites LEADER, a randomized trial published in 2016. It studied heart and blood-vessel outcomes in adults with type 2 diabetes at high heart risk. The claim that liraglutide has established human outcome evidence is graded Supported with scope.
That scope covers approved liraglutide products used in the people and uses that were studied. Saxenda has a separate label for chronic weight management.
The semaglutide record relies on current FDA labels for Ozempic, Rybelsus, and Wegovy. Each label says who the product is for, plus its warnings and side effects. The claim that semaglutide is FDA-approved is graded Supported with scope. It applies only to the exact products, forms, people, and uses in current labels.
Neither record shows the same benefit for every person. The claim that a result in one group proves the same benefit for everyone is graded Not established for semaglutide. The claim that heart trial results prove a longevity benefit for everyone is graded Not established for liraglutide.
The records contain no study that compares liraglutide with semaglutide directly. This page does not say which one works better or leads to more weight loss.
Safety, product, and sports limits
Each current label lists reasons a product may not be right for someone, plus its warnings and side effects. Read the label for the exact product. This page does not decide who can use either one.
Evidence from approved products does not automatically apply to compounded, counterfeit, or research-labeled versions. The claim that compounded semaglutide is the same as an approved product is graded Misleading. FDA says compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before they are sold.
The claim that every product sold as liraglutide is clinically equivalent is also graded Misleading. Product quality and labeling cannot be assumed for every compounded or unapproved item.
The two records differ on sports rules. The liraglutide review on July 23, 2026 did not assess sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
The semaglutide record found no ban in the checked 2026 WADA record on August 30, 2026. WADA monitors markers of semaglutide, and monitoring is not the same as a ban. No dose, schedule, or switching instructions are given here.
Side effects in each FDA label
Each FDA label lists the side effects seen in that product's own placebo-controlled trials. The tables below copy those numbers. Placebo means a shot with no medicine in it. A problem in a table is not proof that the medicine caused it.
The trials studied different people for different lengths of time. The labels say side-effect rates from one medicine's trials cannot be directly compared with rates from another medicine's trials. Compare each number with the placebo number next to it, not with the other table.
The records contain no study that compares liraglutide with semaglutide directly.
One key warning from each label
- Victoza and Saxenda labels: Both labels have a boxed warning, FDA's strongest kind. Liraglutide caused thyroid C-cell tumors in rats and mice. It is not known whether it causes them in people, including medullary thyroid cancer (MTC). People with a personal or family history of MTC, or with a condition called MEN 2, must not use it. The labels list signs of a thyroid tumor to watch for: a lump in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away.
- Ozempic and Wegovy labels: Both labels have a boxed warning, FDA's strongest kind. Semaglutide caused thyroid C-cell tumors in rodents. It is not known whether it causes them in people, including medullary thyroid cancer (MTC). People with a personal or family history of MTC, or with a condition called MEN 2, must not use it. The labels list signs of a thyroid tumor to watch for: a lump in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away.
Each label lists more warnings. See the full tables and notes on each peptide page, linked below.
Victoza vs Ozempic: side effects in the type 2 diabetes labels
Both labels list problems that reached 5% and were more common than on placebo. Each middle column shows the lowest and highest share across two dose groups, so one group can be under 5%. In the Victoza table, one group can also equal placebo.
A problem missing from one table may still have happened, below that label's cutoff or no more often than on placebo. Low blood sugar is left out of both tables. It was more likely when either medicine was taken with insulin or a diabetes medicine called a sulfonylurea.
Compare each Victoza or Ozempic number with its own placebo number.
Victoza trials in adults with type 2 diabetes At least 26 weeks each
Adults with type 2 diabetes in 5 trials. The table counts 1,669 adults on Victoza in two dose groups and 661 on placebo. Low blood sugar is left out of this table.
| Reported problem | Victoza groups | Placebo |
|---|---|---|
| Nausea | 18% to 20% | 5% |
| Diarrhea | 10% to 12% | 4% |
| Headache | 10% to 11% | 7% |
| Colds (nose and throat infections) | 9% to 10% | 8% |
| Vomiting | 6% to 9% | 2% |
| Less hunger | 9% to 10% | 1% |
| Indigestion (dyspepsia) | 4% to 7% | 1% |
| Upper airway infections | 6% to 7% | 6% |
| Constipation | 5% | 1% |
| Back pain | 4% to 5% | 3% |
Source for Victoza trials in adults with type 2 diabetes: Victoza prescribing information on DailyMed , label revised .
Ozempic trials in adults with type 2 diabetes 30 weeks
Adults with type 2 diabetes in 2 trials. One tested Ozempic alone. The other added it to long-acting insulin. 521 adults took Ozempic in two dose groups and 262 took placebo. Low blood sugar is left out of this table.
| Reported problem | Ozempic groups | Placebo |
|---|---|---|
| Nausea | 15.8% to 20.3% | 6.1% |
| Vomiting | 5.0% to 9.2% | 2.3% |
| Diarrhea | 8.5% to 8.8% | 1.9% |
| Belly pain | 5.7% to 7.3% | 4.6% |
| Constipation | 3.1% to 5.0% | 1.5% |
Source for Ozempic trials in adults with type 2 diabetes: Ozempic prescribing information on DailyMed , label revised .
Saxenda vs Wegovy: side effects in the weight-management labels
Both labels list problems in at least 2% of adults on the medicine that were more common than on placebo. These tables show the ones that reached 5%. A problem missing from one table may still have happened, below 5% or no more often than on placebo. Low blood sugar was counted only in people with type 2 diabetes.
The Wegovy table is for the usual-dose shot. Wegovy HD, the Wegovy tablet, and Rybelsus are not in these tables. The rows under 5% and the tables for teens are on each peptide page.
Compare each Saxenda or Wegovy number with its own placebo number.
Saxenda trials in adults with obesity or overweight 32 to 56 weeks, some up to about 3 years
Adults with obesity or overweight in 5 trials. 3,384 got Saxenda and 1,941 got placebo. 15% had type 2 diabetes. Everyone also got advice on diet and exercise.
| Reported problem | Saxenda | Placebo |
|---|---|---|
| Nausea | 39.3% | 13.8% |
| Diarrhea | 20.9% | 9.9% |
| Constipation | 19.4% | 8.5% |
| Vomiting | 15.7% | 3.9% |
| Reactions where the shot was given | 13.9% | 10.5% |
| Headache | 13.6% | 12.6% |
| Low blood sugar (only people with type 2 diabetes were counted) | 12.6% | 6.6% |
| Indigestion (dyspepsia) | 9.6% | 2.7% |
| Tiredness (fatigue) | 7.5% | 4.6% |
| Dizziness | 6.9% | 5.0% |
| Belly pain | 5.4% | 3.1% |
| High lipase, a pancreas enzyme, in blood tests | 5.3% | 2.2% |
| Upper belly pain | 5.1% | 2.7% |
Source for Saxenda trials in adults with obesity or overweight: Saxenda prescribing information on DailyMed , label revised .
Wegovy trials in adults with obesity or overweight Up to 68 weeks
Adults with obesity or overweight in 3 trials. 2,116 got Wegovy and 1,261 got placebo. 19% had type 2 diabetes.
| Reported problem | Wegovy | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Belly pain | 20% | 10% |
| Headache | 14% | 10% |
| Tiredness or weakness (fatigue) | 11% | 5% |
| Indigestion (dyspepsia) | 9% | 3% |
| Dizziness | 8% | 4% |
| Bloated belly | 7% | 5% |
| Burping | 7% | Under 1% |
| Low blood sugar (only people with type 2 diabetes were counted) | 6% | 2% |
| Gas | 6% | 4% |
| Stomach flu (gastroenteritis) | 6% | 4% |
| Acid reflux (GERD) | 5% | 3% |
Source for Wegovy trials in adults with obesity or overweight: Wegovy prescribing information on DailyMed , label revised .
Full tables, notes, and warnings
Report a side effect
You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.
What these records cannot answer
- The reviewed records contain no study that compares liraglutide with semaglutide directly, so no result or weight-loss comparison is made.
- The label side-effect tables come from different trials in different people, so their rates cannot be compared directly between the two.
- The records give no dosing, schedule, titration, or product-switching guidance, and none is given here.
- The liraglutide record did not assess sport eligibility, so this page cannot state it for liraglutide.
- The reviewed records contain no cost, insurance, or availability data, so none is reported.
This page does not provide dosing, sourcing, or treatment advice.
Read the sources behind the comparison
Liraglutide
Semaglutide